Baring India P/E offloads 7.36% in Shilpa Medicare, Tata Sons buys 1% in Tata Motors DVR

Nippon India Mutual Fund was the buyer for some of those shares sold by existing investors

Baring India Private Equity has offloaded its entire equity stake in Shilpa Medicare, the active pharmaceutical ingredients manufacturer, via open market transactions on September 4.

Baring India Private Equity Fund III sold 23.20 lakh shares in Shilpa Medicare at Rs 512.97 per share on the NSE and 36.80 lakh shares at Rs 509.04 per share on the BSE, bulk deals data available on the exchanges showed.

In total, it sold 60 lakh shares (representing 7.36 percent of Shilpa Medicare's total paid-up equity) in the company as of June 30.

Barclays Merchant Bank Singapore also sold 4.5 lakh shares (representing 0.55 percent of its total paid-up equity) at Rs 513.36 per share and Tano Mauritius India FVCI II offloaded 8.5 lakh shares (representing 1.04 percent of its total paid-up equity) at Rs 514.29 per share on the NSE.

Barclays Merchant Bank Singapore held 1.98 percent (16,13,450 shares) and Tano Mauritius India FVCI II 7.58 percent (61,79,506 shares) in Shilpa Medicare as of June 30.

Nippon India Mutual Fund was the buyer for some of those shares sold by existing investors. The fund house acquired 11.25 lakh shares in company at Rs 514.94 per share on the NSE and 10 lakh shares at Rs 515 per share on the BSE. In total, it bought 2.6 percent equity stake in the company.

Among other deals, promoter Tata Sons acquired 53,02,681 shares in Tata Motors DVR 'A' Ordinary (representing 1.04 percent of its total paid-up equity) at Rs 56.02 per share on the NSE.

Rahul Gupta acquired 3,00,200 shares in APL Apollo Tubes at Rs 2,375 per share, whereas Kitara PIIN 1001 sold 5,94,049 shares (representing 2.38 percent of its total paid-up equity) at Rs 2,375.14 per share on the NSE.

Kitara PIIN 1101 held 3.43 percent, or 8.52 lakh shares, in APL Apollo as of June 30.

Perpetuity Health to Wealth Fund sold 1.5 lakh shares in Globus Spirits at Rs 204.14 per share on the NSE.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog